Cardiff Oncology: stockholders approve authorized shares increase

What happened Cardiff Oncology filed an 8-K reporting that it held its Special Meeting of Stockholders on Oct 22, 2026 and stockholders approved an amendment to the Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of capital stock from 170,000,000 to 320,000,000 and increase the number of authorized shares of common stock from 150,000,000 to 300,000,000.

Key details

• A total of 48,084,246 shares of common stock were represented in person or by valid proxies at the Special Meeting.
• The proposal was approved by the votes set forth in the filing: For 37,675,355; Against 10,125,739; Abstain 283,147; Broker non vote 5.
• The filing references the Definitive Proxy Statement filed with the SEC on Aug 26, 2026.

Why it may matter This item was reported under Item 5.07 (Submission of matters to a vote of security holders) and covers the company’s disclosure of the matter submitted to a vote and the voting results. A filing does not show why the insider traded or why the company acted.